High-throughput, targeted MHC class I immunopeptidomics using a functional genetics screening platform

Nat Biotechnol. 2023 Jul;41(7):980-992. doi: 10.1038/s41587-022-01566-x. Epub 2023 Jan 2.

Abstract

Identification of CD8+ T cell epitopes is critical for the development of immunotherapeutics. Existing methods for major histocompatibility complex class I (MHC class I) ligand discovery are time intensive, specialized and unable to interrogate specific proteins on a large scale. Here, we present EpiScan, which uses surface MHC class I levels as a readout for whether a genetically encoded peptide is an MHC class I ligand. Predetermined starting pools composed of >100,000 peptides can be designed using oligonucleotide synthesis, permitting large-scale MHC class I screening. We exploit this programmability of EpiScan to uncover an unappreciated role for cysteine that increases the number of predicted ligands by 9-21%, reveal affinity hierarchies by analysis of biased anchor peptide libraries and screen viral proteomes for MHC class I ligands. Using these data, we generate and iteratively refine peptide binding predictions to create EpiScan Predictor. EpiScan Predictor performs comparably to other state-of-the-art MHC class I peptide binding prediction algorithms without suffering from underrepresentation of cysteine-containing peptides. Thus, targeted immunopeptidomics using EpiScan will accelerate CD8+ T cell epitope discovery toward the goal of individual-specific immunotherapeutics.

MeSH terms

  • Cysteine*
  • Epitopes, T-Lymphocyte / genetics
  • Histocompatibility Antigens Class I* / genetics
  • Histocompatibility Antigens Class I* / metabolism
  • Ligands
  • Peptides / metabolism
  • Protein Binding

Substances

  • Ligands
  • Cysteine
  • Histocompatibility Antigens Class I
  • Peptides
  • Epitopes, T-Lymphocyte